Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

155
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
155
Drug Distribution: Tissue Binding01:21

Drug Distribution: Tissue Binding

2.6K
Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
2.6K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

318
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
318
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

715
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
715
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

167
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
167
Drug Distribution: Volume of Distribution01:25

Drug Distribution: Volume of Distribution

5.0K
The volume of distribution refers to the theoretical volume necessary to contain the entire amount of an administered drug at the same concentration observed in the blood plasma. The body's intracellular fluid compartment, which makes up two-thirds of the total body water, is contrasted with the extracellular fluid compartment—comprising plasma and interstitial fluid—that accounts for one-third. The volume of distribution can vary depending on the characteristics of the drug.
5.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Author Correction: Programming local confinements in crystalline frameworks through reticular chemistry.

Nature materials·2026
Same author

Programming local confinements in crystalline frameworks through reticular chemistry.

Nature materials·2026
Same author

Limitations of Serum Bicarbonate as a Criterion for Metabolic Acidosis in CKD: Implications for Clinical Trials.

Journal of the American Society of Nephrology : JASN·2026
Same author

Severe Acute Hypertension Causes Hemolysis With Release of PEP and ACE Inhibitor.

Hypertension (Dallas, Tex. : 1979)·2026
Same author

Short-Term Dietary Potassium Deprivation Induces Intense Kidney Sodium Retention.

Circulation research·2026
Same author

Reversible Addition-Fragmentation Chain-Transfer Aqueous Emulsion Polymerization Observed by Transmission Electron Microscopy.

Journal of the American Chemical Society·2026

Related Experiment Video

Updated: Jun 26, 2025

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

217

Long-Circulating Vasoactive 1,18-Octadecanedioic Acid-Terlipressin Conjugate.

Or Berger1, Wonmin Choi1, Caroline H Ko2

  • 1Department of Chemistry, Northwestern University, Evanston, Illinois 60208, United States.

ACS Pharmacology & Translational Science
|May 16, 2024
PubMed
Summary

A new terlipressin conjugate (ODDA-TP) shows improved efficacy and safety for hepatorenal syndrome (HRS). This albumin-binding peptide offers a promising therapeutic advancement for liver disease complications.

More Related Videos

Heterotopic Auxiliary Rat Liver Transplantation With Flow-regulated Portal Vein Arterialization in Acute Hepatic Failure
16:19

Heterotopic Auxiliary Rat Liver Transplantation With Flow-regulated Portal Vein Arterialization in Acute Hepatic Failure

Published on: September 13, 2014

12.7K
Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
08:44

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema

Published on: September 1, 2016

8.9K

Related Experiment Videos

Last Updated: Jun 26, 2025

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

217
Heterotopic Auxiliary Rat Liver Transplantation With Flow-regulated Portal Vein Arterialization in Acute Hepatic Failure
16:19

Heterotopic Auxiliary Rat Liver Transplantation With Flow-regulated Portal Vein Arterialization in Acute Hepatic Failure

Published on: September 13, 2014

12.7K
Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
08:44

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema

Published on: September 1, 2016

8.9K

Area of Science:

  • Pharmacology
  • Hepatology
  • Drug Development

Background:

  • Hepatorenal syndrome (HRS) is a severe complication of end-stage liver disease with limited treatment options.
  • Terlipressin (TP) is a vasopressin analogue used for HRS, but it has short circulation half-lives and potential side effects.
  • Recent US approval of TP highlights the need for improved HRS therapies.

Purpose of the Study:

  • To develop and evaluate a novel conjugate of terlipressin (TP) with 1,18-octadecanedioic acid (ODDA).
  • To assess the noncovalent albumin-binding properties and therapeutic potential of ODDA-TP.
  • To compare the efficacy, pharmacokinetics, and safety of ODDA-TP against TP alone.

Main Methods:

  • Synthesis of the 1,18-octadecanedioic acid (ODDA) conjugate of terlipressin (ODDA-TP).
  • In vitro studies assessing cellular receptor activation and plasma stability.
  • In vivo pharmacokinetic and safety evaluations in rat models.

Main Results:

  • ODDA-TP demonstrated enhanced stability in plasma and superior in vitro cellular receptor activation compared to TP.
  • Pharmacokinetic studies revealed an elimination half-life 20 times longer for ODDA-TP than for TP.
  • ODDA-TP exhibited a superior safety profile in preclinical evaluations.

Conclusions:

  • The ODDA-TP conjugate offers a promising new therapeutic strategy for managing hepatorenal syndrome.
  • Albumin binding via ODDA conjugation significantly improves TP's pharmacokinetic and safety profile.
  • ODDA-TP represents a potential advancement in treating life-threatening liver disease complications.